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Abstract
The association between tuberculosis (TB) and diabetes mellitus (DM) had a common place in the 
literature up to the first half of the 20th century, but virtually disappeared with the discovery of 
insulin to treat DM and antibiotics to cure TB. In the late 1990s the literature began to re-emerge 
with the worldwide increase in type 2 DM, particularly in TB-endemic countries. Today, type 2 
DM is the most prevalent comorbidity among TB patients and the World Health Organization 
considers it a threat to TB control. We summarize the literature on TB and DM up to the 1960s. 
Then we evaluate unique aspects of this comorbidity in older times, such as the frequent diabetic 
comas that suggest challenges for proper DM management as insulin was being implemented, or 
the absence of antibiotics to cure TB. Despite the unique aspects of each study period, the 
literature across times is consistent in key aspects of the association. Namely, a higher TB 
prevalence among DM (versus non-DM patients), the importance of glucose control and chronic 
DM on TB susceptibility and the higher risk of death among patients with the comorbidity. From 
the older literature, we can infer the likely contribution of type 1 DM to TB (in addition to type 2), 
regardless of their differing autoimmune or metabolic pathophysiology, respectively. Furthermore, 
in the older literature there was a notable reporting of DM development among TB patients, even 
though DM usually preceded TB. This observation deserves further epidemiological and basic 
studies to elucidate this intriguing aspect of the relationship between TB and DM.
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1. Introduction
The medical profession has been intrigued for centuries by the complex interactions between 
the alterations in the metabolism caused by diabetes mellitus (DM), its associated 
impairment in immune function, and its relationship to heightened susceptibility to 
infections, including pulmonary tuberculosis (TB). In the early and mid-years of the 20th 
century, hallmark events occurred in the management of patients with DM and TB: the 
introduction of insulin into the clinical practice in 1923 to improve glucose control, and the 
discovery and implementation of effective antibiotics for the treatment of TB between the 
1940s and 1970s [1]. In this review, we provide a historical perspective on the epidemiology, 
clinical observations and management of patients with DM and TB. Then we present a 
summary of the literature on the association between both diseases, with emphasis on 
studies conducted up to the first half of the 20th century. Then we evaluate how these 
historical perspectives enrich our understanding of this re-emerging association.
2. Overview and brief history of DM and TB
DM is a syndrome characterized by chronic increase in blood glucose as a result of defects 
in insulin secretion, the action of insulin or a combination of both [2]. DM has been 
classically divided in two major groups: Type 1 DM is an autoimmune disease the results in 
the destruction of pancreatic beta cells and inability to produce insulin. Type 2 DM is 
characterized by insulin resistance and associated with obesity [3]. A key aspect in the 
history of DM was the discovery of insulin, which started in 1869 when a German medical 
student, Paul Langerhans , described the pancreatic islets [4]. After several failed attempts 
by numerous researchers to use the pancreatic islet concentrates to treat DM, Frederic 
Banting and John Macleod at London Western University successfully dogs after 
pancreatectomy [5]. They reported these findings in 1921 at the meeting of the produced 
pancreatic extracts that prolonged the survival of American Medical Association. There 
were subsequent improvements of the extract, and in 1923 the pharmaceutical company Eli 
Lilly began the mass production of insulin in the US, and Banting and Macleod received the 
Nobel price for their achievement [4].
DM is currently a global pandemic, and its worldwide prevalence has increased from 4-5% 
in 1980 to 8-9% in 2014 [6]. In the US, DM has also increased between 2002 and 2012 
among younger populations, aged <20 years, at a relative annual rate of about 1.8% for type 
1 DM and 4.8% in type 2 DM, after adjusting for confounders [7]. The diagnostic criteria for 
DM has evolved over time as its underlying pathophysiology is better understood. For 
centuries, the diagnosis was based on symptoms (e.g. thirst, polyuria, weight loss and 
comma) and the presence of sweet urine [8]. In the 18th century the cause of sweetness in 
urine was discovered to be due to excess sugar, and to be accompanied by high blood 
glucose [8]. In contemporary times, the biomarkers to define DM have been further 
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evolving, with the use of fasting plasma glucose, a 2h oral glucose tolerance test, and most 
recently, HbA1c [2, 9]. Collectively, the introduction of new biomarkers and updated cut-off 
points for diabetes diagnosis is likely to increase prevalence estimates, but there is 
acceptance of a worldwide net increase in DM that is driven by excess population obesity 
[9].
Chronic hyperglycemia is characterized by glucotoxicity that affects multiple organs leading 
to a number of comorbidities (i.e. micro- and macrovascular diseases, gestational DM, 
depression). Chronic hyperglycemia also affects immune surveillance, which contributes to 
the higher risk of morbidity and mortality from certain types of infections. Today, type 1 
DM is treated with insulin and T2D is most commonly managed with oral anti-diabetic 
drugs like metformin to increase peripheral glucose use and sulfonyureas to promote 
pancreatic insulin secretion. Insulin is ultimately added when the patient’s pancreas has lost 
capacity to produce insulin [2]. In this review, we focus on the association between DM 
(types 1 and 2) and pulmonary TB, a comorbidity reported since antiquity and a re-emerging 
concern in contemporary times [10].
Mycobacterium tuberculosis is the etiological agent of TB, an airborne infectious disease. In 
Ancient Greece, Hippocrates described TB as phthisis (“to waste away”). Avicenna 
(980-1037) described TB as caused by “body humors perverted on their behavior” [11]. The 
infectious nature of TB was demostrated by Jean-Antoine Villemin in 1865, when he 
observed that recruits in barracks developed TB more often, and showed that rabbits 
inoculated with “purulent material” from patients that died of TB had extensive disease on 
autopsy [12]. Robert Koch discovered the microbe behind TB, Mycobacterium tuberculosis, 
and presented his findings to the Society of Physiology in Berlin in 1882 [13]. TB was 
widespread in Europe after the decline of the Roman Empire. The industrial revolution was 
associated with overcrowding and poor ventilated living areas and around 1838 up to one-
third of the English tradesman and employees died of TB. Today, TB is the ninth leading 
cause of death in the world, with about 10.4 million new TB cases and 1.67 million deaths a 
year [14]. TB therapy has evolved over centuries. During the 19th century, sanatoria were 
developed. In 1944 streptomycin and para-aminosalicilic acid were discovered. This success 
was followed by the discovery of isoniazid in 1951, ethambutol and rifampin in the 1960’s, 
and pyrazinamide in 1972 [1].
3. TB and DM: What we learned up to the first half of the 20th century
The earliest reports on the association between DM and TB include the descriptions by the 
Persian philosopher Avicenna in the 10th century, and an Indian siddhar, Yugimahamuni, 
who described the progression of obesity to impotence, thirst, glycosuria, and ultimately to 
TB [11, 15]. The association between TB and DM had a common place in the literature up 
the first half of the 20th century, but it diminished with the discovery and use of insulin for 
DM in the 1920s, and virtually disappeared with the implementation of antibiotics to treat 
TB in the 1960s. In the 1980s the advent of HIV/AIDS took center stage in the TB literature 
and remains the largest risk factor for TB at the individual level, with approximately 20-37 
fold higher risk of TB [16]. But with the increasing number of DM patients worldwide, 
particularly in countries where TB is also endemic, there has been a re-emergence of 
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literature on the concurrence of TB and DM since the late 1990s, with an exponential 
increase in the number of publications in the most recent years[19, 20, 21] (Figure 1). 
Details on the current state of the association between both diseases are provided elsewhere 
[17, 18]. In this section, we focus on the studies published in the latter part of the 19th 
century and first half of the 20th century, with emphasis on four studies published between 
1931 and 1958 that provide the most detailed descriptions for these times. We first describe 
their study designs to point out differences in the methodology used during these older times 
(Table 1), and then compare their findings to the contemporary literature (late 1990s to 
today).
3.1 Study designs
In 1931 Andrew L. Banyai published a literature review on the prevalence, clinical 
presentation and outcomes of patients with TB and DM [19]. In the same manuscript, he 
*described the findings from a cross-sectional study he conducted on the association 
between TB and DM among 5,224 patients of all ages admitted with TB to the Muirdale 
sanatorium in Wisconsin between 1923 and 1929 (Table 1) [19].
In 1932 Howard Root reported the results of two studies he conducted to evaluate TB 
prevalence in DM patients at the New England Deaconess Hospital in Massachusetts. One 
was from 1,000 autopsies and the second one was from 1,659 chest x-rays (Table 1)[20]. He 
studied individuals of all ages but sample sizes were not specified. The information he 
collected was compared to other epidemiological studies, vital statistics and TB surveillance 
reports in the US. He also summarized the data from previous prevalence studies of TB 
among DM patients or in the general population (Figure 2).
In 1952, Katherine Boucot and collaborators published the results of “The Philadelphia 
Study” conducted from December 1945 to 1957. They enrolled diabetic patients (n=3,106) 
of all ages that were consecutively referred by private practice providers to four hospital 
clinics in Philadelphia and screened them for TB. TB (active or inactive) was based on 
photofluorography, a photograph of x-rays under fluorescent light to show the extent of lung 
involvement. DM was defined as blood glucose over 200 mg/dL or an abnormal oral glucose 
tolerance test (Table 1). There were unique aspects of this study’s design for these times. 
First, they used blood glucose to diagnose DM. Second, they classified glucose control 
based on the last five blood sugar measurements, as follows: Poor, if at least four readings 
were ≥200 mg/dL; fair, if at least three measurements were ≥200 mg/dL; and good, if all are 
<200 mg/dL. Third, they defined DM severity based on the requirement for insulin: none, 
1-40 units or more than 40 units. Fourth, the physicians reading the photofluorography were 
blinded regarding the DM status of the participants. Fifth, they did an age and sex-matched 
comparison of the prevalence of TB among DM patients against an existing database from a 
survey reporting the prevalence of TB in 71,767 Philadelphia industrial health workers.
In 1958, Hans Silwer and P. Oscarsson performed an epidemiological study in two phases 
[21]. First they evaluated the prevalence of DM in the entire county of Kristianstad in 
Sweden. They used several strategies to identify all the DM patients. First, they searched 
hospital records for patients with insulin prescription, since there was universal coverage if 
the patient presented a certificate of their diagnosis. Second, they sent letters to practices 
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outside the hospitals to detect DM patients not requiring insulin. Third, they enlisted social 
workers and parish members to locate diabetics that would not be otherwise found. Then 
they used census data to calculate the prevalence of DM in the county. In the second phase, 
they conducted a nested study to determine the prevalence of TB among individuals with 
DM. From 1326 diabetics identified, 1270 underwent radiological examination to investigate 
evidence of TB infection.
Several observations distinguish the study designs from the older literature. First, TB 
diagnosis relied largely on radiological methods, autopsy findings or referrals to 
sanatoriums. Thus, TB included active TB, lesions from healed TB, other forms of TB 
disease or latent TB infection. These methods lack specificity and the authors noted a 
possible over-diagnosis of TB. In current times, clinical signs and symptoms compatible 
with TB are complemented with the detection of acid fast bacilli by smear microscopy or 
pathology, and when available, by confirmation of M. tuberculosis by culture or detection of 
nucleic acids. Today we use the tuberculin skin test (developed in 1934) and interferon 
gamma release assays to help diagnose infection in non-symptomatic patients [22]. Second, 
a case definition for DM was rarely specified in the older literature and HbA1c was not 
available. In the Philadelphia study, DM severity was based on the units of insulin required, 
but access to insulin seemed more readily available to the higher classes. Third, studies 
suffered from selection bias due to the inclusion of convenience samples, with heterogeneity 
in host characteristics, including the inclusion of individuals dying at hospitals, a scenario 
more common among the lower socioeconomic classes. Today, most studies on TB and DM 
are done in adults, given the higher prevalence of the co-morbidity among those 35 years or 
older.
3.2 Results of older studies and comparison with the contemporary literature
3.2.1 Increasing DM prevalence among TB patients after the introduction of 
insulin—Banyai noted that around 1919 the prevalence of DM among TB patients in 
sanatoriums was about 0.17- 0.33% [19]. In his study in the 1930’s this proportion was 
about two-fold higher (0.59%) in the general population, and he attributed this change to the 
increased number of DM patients and the better life expectancy of TB-DM patients since the 
introduction of insulin. Today this proportion is significantly higher, with some communities 
reporting nearly 40% or 50% DM among TB patients [23–25]. This sharp surge in DM in 
less than one century is a reflection of the worldwide increase in obesity, particularly in 
lower and middle income countries where TB is endemic [17].
3.2.2 Higher TB prevalence among DM versus non-DM patients—In the 19th 
century, a challenge to determine if TB was more prevalent among DM versus non-DM 
individuals was the high background of past or present TB in the general population [20]. 
For example, a study examining autopsies in the general population in Zurich in the 1900s 
attested that 97% of those who died of any cause had evidence of active or inactive TB [20]. 
But the prevalence of TB in the general population was lowering at the turn of the 20th 
century, and a similar decrease was observed among DM patients (Figure 2). Despite these 
dynamics, the older studies consistently concluded a higher prevalence of TB in DM 
patients. For example, Root took the data from 10 studies done in general population and 15 
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studies done in DM patients only, and calculated the average frequency of TB in each group. 
He concluded for the same studies shown in Figure 2, that the prevalence of TB was higher 
among DM patients (35.8%) versus the general population (23.0%; Table 2). Root also 
concluded from his own studies that diabetic children were 13 times more likely to have 
evidence of pulmonary TB versus non-diabetic [20]. Banyai estimated that the prevalence of 
TB was about 3 times higher in patients with DM than in the general population [19]. The 
Philadelphia study concluded that prevalence of TB among diabetics was higher than among 
non-diabetics (8.4% vs 4.3%) [26], and Silwer and Oscarsson found that the prevalence of 
TB was 3.6% in DM and 0.9% in the non-DM patients (Table 2) [21].
Even though these earlier studies reported that TB was more frequent among DM patients 
than in the general population, distinguishing a “coincidence” versus a true association 
between both diseases was difficult due to several limitations. First, most studies reported on 
the prevalence of TB among DM patients only, but did not include a non-DM group as 
reference [19, 20]. Therefore, comparisons were done between different studies as reported 
by Root, and this was further complicated by the rapid decrease of TB and parallel increase 
in DM in the general populations. Second, there was marked heterogeneity in study 
populations within and between studies with respect to age, ethnicity, socioeconomic status 
or diagnostic criteria for TB or DM, among others. For example, Boucot et al reported that 
the proportion of non-white population (surrogate for lower socio-economic strata) was 
about double the percentage of non-white individuals living in Philadelphia at the time, an 
indication that the study sample was not representative of the general population [26]. This 
was expected in the study population (not the general population), given that poor DM 
control and TB were more frequent among the lower classes. Silwer and Oscarsson reported 
that DM was associated with increased weight, higher standard of living and older age [21]. 
We noted that studies diagnosing TB based on autopsies reported higher TB prevalences 
when compared to those using radiological methods (Table 2). However, data was not 
stratified by these variable factors, and statistical tools were not available to determine if DM 
was an independent predictor for higher TB after controlling for possible confounders. 
Furthermore, the statistical analysis to determine if two proportions were significantly 
different was either not conducted or the method not specified. We used statistical tools 
available today to evaluate and interpret some of the older observations. For example, for the 
studies listed in Figure 2, Root estimated that the TB frequency was 23% in the general 
population and 35.8% in DM. He further concluded that TB was “more” prevalent in DM. 
We conducted a meta-analysis with random-effects on these same studies with Stata (release 
15, StataCorp TX, USA). We found that the TB prevalence was 26% (95% CI: 19, 33) for 
general population and 32% (95% CI 23, 42) for DM, and noted that estimations had 
substantial overlapping on 95% confidence intervals. For these same studies, Root also noted 
there was a decrease in TB prevalence over time in the general population and in DM 
patients. To measure this change in TB prevalence in the general population or among DM 
patients, we performed a meta-regression of TB prevalence on year of study. We found a 
decrease in TB prevalence per year of 0.6% (95% CI −0.2%, −0.7%) or 0.5% (−0.2%, 
−0.8%) for the general population and for diabetics, respectively (Figure S1).
Another difference between the older and contemporary times is the high prevalence of TB 
in the general population from the late 19th and early 20th centuries (26% in Figure 2). 
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Today, active TB burden is measured by incidence (not prevalence) because it is curable. 
The current TB incidence is at historic low rate for the developed countries where these 
older studies were conducted (e.g. less than 3.0/100,000 in the US), and is highest in 
countries with low incomes or high HIV burdens (e.g. 781/100,000 in South Africa).[14, 27] 
Thus, the WHO only recommends routine screening for active TB among DM patients in 
high-burden countries [28, 29]. Also, today’s cohort studies aimed at evaluating the 
development of TB among DM versus non-DM patients require tens of thousands of 
participants [30].
3.2.3 Association between TB and DM by DM severity and chronicity, 
stratified by age—Boucot et al and Silwer and Oscarsson found that among all the DM 
patients, those with severe DM or more than 10 years with DM, were more likely to have 
active TB (Figure 3). This was observed across all age groups, but the difference was more 
notable in the younger DM patients, who were more likely to have severe DM. The authors 
noted this when measuring DM severity based on insulin requirements as shown in Figure 
3B, and Boucot et al reported higher TB among diabetics younger than 40 years with a 
history of diabetic coma (9.6%) versus those without diabetic coma (5.3%). Similar findings 
were generally observed when all TB forms (active or inactive) were evaluated with respect 
to DM severity or duration, but results were not as consistent as for active TB forms only 
(data not shown). Despite the high prevalence of TB among the young TB patients with 
severe DM, most of the TB-DM patients were 40 years or older, for both active and inactive 
TB (Figure S2) [21, 26].
Several of these older observations are comparable with the contemporary TB-DM 
literature. The first is the higher prevalence of DM in TB patients who are 40 years or older, 
who are not as likely to have a diabetic coma or severe DM, and who have a body weight 
“above the normal” (51% vs 30%) [31]. Thus, most of the DM patient with TB in the older 
literature appeared to be type 2 DM, a finding comparable with contemporary studies. 
Today, type 2 DM accounts for 95% of the DM cases and most studies on TB-DM are done 
in adults. The second observation from the older studies is that TB was more prevalent in the 
DM patients with poor glucose control and/or more than 10 years of DM (Figure 3). These 
findings are consistent with the current epidemiological studies showing that TB is most 
prevalent among the DM patients with poor glucose control or a multi-year history of DM 
[32–35]. Basic science studies further show that the immune cells from DM patients with 
high HbA1c (an indication of chronic hyperglycemia when above 6.5%), versus normal 
HbA1c have the most notable alterations in function, and animal studies show that 
compromised immunity and high M. tuberculosis burden is observed only in chronic 
hyperglycemia [36–40]. The mechanisms by which chronic hyperglycemia leads to 
alterations in immune function that can compromise immune surveillance against M. 
tuberculosis is shown in Figure 4 [18, 41, 42].
The older literature also provides additional knowledge to our contemporary understanding 
of the TB-DM association given the higher prevalence of TB among young patients with a 
history of diabetic coma or requiring high doses of insulin. This clinical presentation is 
characteristic of type 1 DM and its frequent reporting in the older literature provides further 
support for the contribution of type 1 DM to TB. This is a poorly studied aspect of the TB-
Cadena et al. Page 7













DM association today due to the low frequency of type 1 DM (~5%) [43]. The underlying 
pathology in type 1 DM is autoimmune in nature, while in type 2 DM it is metabolic and 
associated with obesity. Given the apparent contribution of both types of DM to TB, then 
one can speculate that the higher risk of TB in DM patients is attributed to the negative 
downstream consequences of a chronic and poorly controlled hyperglycemia (Figure 4). 
These findings are in line with the immune response alterations noted in humans and in 
animal models of TB-DM [18, 39, 40, 44, 45]. However, the additional contribution to TB 
risk conferred by autoimmune or metabolic abnormalities in type 1 or type 2 DM, 
respectively, cannot be ruled out [43, 46].
3.2.4 Is the association between TB and DM bi-directional?—Banyai reported 
that although TB was more common among DM patients, the relationship between DM and 
TB may be bidirectional with carbohydrate intolerance developing during the later stages of 
TB disease [19]. He reported on previous experimental studies in rabbits, where “toxemia” 
caused carbohydrate intolerance, for example, when rabbits were exposed to diphtheria 
toxin. He also reported cases of experimental models on rabbits and guinea pigs that became 
hypoglycemic when inoculated with TB, and later some became hyperglycemic due to 
atrophy and necrosis of the pancreas [19]. Root examined the coinfection of TB and DM, 
and proposed that TB developed more frequently among DM patients, but he did report that 
1.5% of the TB patients developed DM as a complication of TB [20]. Silwer reported that 
the relationship between TB and DM seemed to be bidirectional, with DM patients showing 
a higher prevalence of TB, and vice versa [21].
Together, most evidence supported a progression from DM to TB, which is consistent with 
the current literature [30]. However, there are also frequent reports of TB exacerbating 
glucose control among patients who already had DM, or predisposing to the development of 
DM. These observations have two probable explanations. The first is that “DM” in these 
cases is in fact a transient hyperglycemia as a consequence of the febrile presentation of TB 
[42, 47]. The second possibility is that there is indeed a higher risk for DM development 
among individuals with TB. In this regard, Banyai summarized published observations on 
experimental studies with rabbits suggesting that an infection with M. tuberculosis can 
promote necrosis and atrophy of the pancreas resulting in a permanent reduction of 
functional capacity[19]. In contemporary times, the higher risk of DM among individuals 
with a history of TB has also been suggested but evidence is scanty [17]. A plausible 
mechanism is that the febrile process associated with TB induces insulin resistance, with 
overstimulation of the pancreatic β-cells to produce insulin. If this process is severe and 
chronic, the prolonged stress induces pancreatic β-cell apoptosis that results in permanent 
damage [48]. Given the lack of antibiotics during the early part of the 20th century, we 
predict that patients who survived chronic episodes of TB would indeed be more vulnerable 
to this pathology when compared to the TB patients from today who have access to anti-
mycobacterial treatment with shorter episodes of TB and a permanent cure in most cases. 
However, in contemporary times this can also happen, particularly in individuals in the 
lowest socio-economic strata who do not have ready access to healthcare, and may have 
delayed TB diagnosis and treatment.
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3.2.5 Are TB outcomes worse in patients with TB and DM?—Banyai attributed 
the poor outcomes among patients with DM who developed TB to a number of factors: i) the 
late detection of TB among DM cases, ii) the late diagnosis and difficult treatment of DM, 
iii) the delay in admission to a sanatorium to treat TB, iv) the lack of proper TB therapy 
(including surgical care), v) the complications of advanced TB such as dissemination to 
extra-pulmonary sites and pneumothorax, vi) the poor socioeconomic status of the patient, 
and vii) the non-TB and non-DM complications associated with older age such as coronary 
artery disease [19]. The calculated life expectancy of TB-DM patients at the time of TB 
diagnosis was 63% at one year, 23% at 3 years, 13% more than 3 years, and only 1% 
completely resolved. From his own series (n=31), Banyai reported that 32% of the patients 
died, 45% did not improve, 16% improved and 6% became quiescent. TB treatment 
consisted of admission to a sanatorium and increase protein, fat and carbohydrate intake, and 
DM was managed with insulin [19]. Root reported that the overall TB death rate among 
diabetics increased over time from 4.7% before June 1919 to 6.7% between 1922 and 1931, 
despite decrease in mortality in the community. He observed that most of the young patients 
with TB would die at an early age. Root raised the possibility that inadequate reporting and 
bias in the literature could contribute to inaccurate measurement of TB mortality. For 
example, he reported that individuals from poor socioeconomic strata tended to die more 
often in hospitals, and these were usually the reported cases. He also indicated that before 
the availability of therapy for DM, most of the diabetics who survived the complications of 
DM were likely to die from TB [20].
The Philadelphia survey’s authors noted that TB tended to present a more acute course 
among patients with DM [26]. Silwer and Oscarsson reported that death due to TB at one 
year was 21% and this progressed to 65% at 10 years, while death due to other causes 
among TB-no DM patients was only 9% at 10 years [21].
In summary, the cross-sectional design of these four studies are not ideal to determine 
whether outcomes were more severe in the TB-DM patients versus TB without DM. 
However, based on the reported comparisons and prevalence of death among the co-infected 
patients, in the 19th century up to the latter part of the 20th century, TB was a regular 
accompaniment of DM and among those patients who did not die in coma, TB was a 
common cause of death. The coincidence of TB and DM was particularly common in the 
poorer classes. Today, most studies suggest that DM patients are also more likely to die 
during the course of TB treatment.
However, as indicated in this older literature, the cause of death may not necessarily be TB, 
but rather, DM complications such as cardiovascular diseases [17, 46, 49]. Today there is 
also evidence for other adverse outcomes in TB-DM patients (versus TB-no DM), such as 
delayed clearance of M. tuberculosis during the course of treatment based on AFB smears or 
cultures, but these protocols were not established in the early 20th century [50]. Today we 
also know that TB-DM patients are more likely to fail treatment or relapse [17, 51].
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Even though the older literature suffered from a number of limitations in their study designs, 
conclusions can be draw given the overall consistency in the observations between studies, 
and the high number of individuals studied. A unique aspect of this literature when 
compared to contemporary times was the absence of antibiotics to treat TB, and the frequent 
reporting of diabetic comas despite the implementation of insulin to manage DM. This 
literature reiterates the higher frequency of the co-morbidity, the higher risk among those 
DM patients with poor glucose control and multi-year history of DM, regardless of their age, 
and the higher risk of complications in these patients, notably death. This literature also 
provides support for the higher risk of TB among patients with type 1 DM, which is difficult 
to study today. Furthermore, it also provides support for the higher risk of DM development 
among individuals with a chronic history of TB. This is an intriguing observation that 
warrants further epidemiological and basic science studies in contemporary times [17].
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Figure 1. The re-emerging association between TB and DM based on indexed publications.
The number of “journal articles” published in English with titles containing the words 
“diabetes” and “tuberculosis” and indexed in PubMed between 1900 and 2017 is plotted by 
year. The association between TB and DM was first reported by Avicenna in the 10th century 
(not shown) and the comorbidity had a common place in the literature up to the first half of 
the 20th century. In 1921 insulin was introduced to treat DM, which appeared to reduce the 
prevalence of TB in these patients due improvements in glucose control. With the additional 
discovery of antibiotics to cure TB between the 1940s and 1970s, the literature on the 
comorbidity virtually disappeared. In the 1980s and 1990s the emergence of HIV took center 
stage in the TB literature, but in the early 2000s there was a re-emergence in publications 
that paralleled the contemporary DM pandemic. RIF, rifampicin; INH, isoniazid, EMB, 
ethambutol; PZA, pyrazinamide.
Cadena et al. Page 15













Figure 2. Meta-analysis of TB prevalence by DM status based on autopsy studies (1859-1934).
The proportion of TB in the general population or in DM patients only was evaluated for 
studies published between 1859 and 1934. All studies conducted autopsies to diagnose TB. 
Studies are listed in chronological order to show the parallel reduction in TB prevalence in 
the general population or in DM patients at the turn of the 20th century. TB refers to autopsy 
findings suggestive of active or inactive TB; ES, Estimation of proportion; Data on TB 
proportion and population sizes was obtained from the literature reviews from Root (1932) 
and the autopsy study done by Root (1932).
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Figure 3. Proportion of active TB among DM patients by severity or duration of DM, stratified 
by age.
A. Severity of DM at the time of TB diagnosis, defined by Boucot et al as mild if requiring 
no insulin, moderate if requiring <40 U and severe if requiring ≥ 40 U. In Silwer and 
Oscarsson, mild DM was defined as requiring less than 20 U of insulin, severe DM if 
requiring ≥ 40 U, had tendency to acidosis, repeated comma attacks and was difficult to 
regulate, and moderate DM was the category in between mild and severe. B. History of DM 
prior to TB development. In Silwer and Oscarsson, < 10 yrs with DM refers to 5-9 years.
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Figure 4. From chronic glucose excess to glucotoxicity that can lead to compromised immunity.
During normoglycemia, glucose is oxidized through the glycolysis, tricarboxylic acid cycle 
and oxidative phosphorylation for efficient generation of ATP and reducing power (green 
text). During the chronic hyperglycemia resulting from type 1 or type 2 DM, excess glucose 
swamps the glycolytic pathway and inhibits the catabolism of glyceraldehydes, leading to 
the abnormal and excess shunting of the up-stream metabolic intermediates to other 
pathways (red font). These shunting pathways enhance the accumulation of reactive oxygen 
species that cause chronic oxidative stress. The reactive oxidative species cause micro- and 
macrovascular damage and induce chronic inflammation (referred to meta-inflammation in 
the case of metabolic alterations associated with type 2 DM). We posit that these alterations 
jointly contribute to compromised immune responses, contributing to the higher risk of DM 
patients to TB, particularly those with poor glucose control. P, phosphate group; PKC, 
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protein kinase C; AGE, Advanced glycation end product; RAGE, receptor for AGE.; TCA, 
tricarboxylic acid cycle; Only selected intermediates of the glycolysis pathway are shown.
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